Topics

Catalent signs agreement for first-in-class oncological therapy

06:25 EST 12 Feb 2020 | Manufacturing Chemist

Zumutor Biologics has chosen Catalent to provide process optimisation and drug substance manufacturing services

Original Article: Catalent signs agreement for first-in-class oncological therapy

NEXT ARTICLE

More From BioPortfolio on "Catalent signs agreement for first-in-class oncological therapy"

Quick Search

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...